Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary) ; Bevacizumab
- Indications Solid tumours
- Focus Therapeutic Use
- 15 Sep 2011 Planned End Date changed from 1 Oct 2010 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 14 Nov 2008 New trial record.